RELATED STORY | FDA panel rejects the use of psychedelic drug MDMA to treat patients with PTSD Lykos said the issues FDA raised in what's called a complete response letter echoed the concerns ...

The Food and Drug Administration (FDA) panel voted 10-1 against endorsing the safety of MDMA in treating PTSD, and 9-2 against ... be used as a rationale to reject the treatment.

A first-of-a-kind proposal to begin using the mind-altering drug MDMA as a treatment for PTSD was roundly criticized Tuesday — a potentially major setback to psychedelic advocates who hope to ...

The FDA has denied Lykos Therapeutics' marketing application for its post-traumatic stress disorder (PTSD) therapy based on MDMA, also known as ecstasy, in a setback for the emerging psychedelic ...

the U.S. Food and Drug Administration (FDA) made the decision not to approve MDMA-assisted therapy for post-traumatic stress disorder. This decision comes just months after advisors to the agency ...

The Texas House and Senate have approved a new state fund for research into ibogaine, which has been used by veterans to ...

Multidisciplinary Association for Psychedelic Studies (MAPS), the FDA has agreed study designs for two phase 3 studies assessing MDMA-assisted psychotherapy for patients with severe PTSD.

The same might soon happen with MDMA (a.k.a., ecstasy), the party drug that’s showing great promise in treating PTSD and other anxiety-related disorders. DON’T MISS: Answers to burning ...

Kaya Holdings Advocates For Psilocybin As FDA Rejects MDMA For PTSD Treatment Kaya Holdings criticizes the FDA's rejection of MDMA therapy for PTSD, proposing psilocybin as a viable alternative ...

or administering), the FDA labeled MDMA-assisted psychotherapy a “beakthrough therapy” for PTSD in 2017. (Schedule I drugs are substances considered to have “no currently accepted medical ...

Although that seems promising, the FDA’s decision last year to reject public use of MDMA-assisted therapy for PTSD created a major setback for researchers and patients, according to experts.